# A Study Of Oral PF-02341066, A C-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced Cancer

> **NCT00585195** · PHASE1 · COMPLETED · sponsor: **Pfizer** · enrollment: 596 (actual)

## Conditions studied

- Non-Small Cell Lung Cancer ALK-positive
- Non-Small Cell Lung Cancer c-Met Dependent
- Non-Small Cell Lung Cancer ROS Marker Positive
- Systemic Anaplastic Large-Cell Lymphoma
- Advanced Malignancies Except Leukemia

## Interventions

- **DRUG:** PF-02341066
- **DRUG:** Rifampin
- **DRUG:** Itraconazole

## Key facts

- **NCT ID:** NCT00585195
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-04-19
- **Primary completion:** 2020-07-30
- **Final completion:** 2022-01-19
- **Target enrollment:** 596 (ACTUAL)
- **Last updated:** 2023-02-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00585195

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00585195, "A Study Of Oral PF-02341066, A C-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced Cancer". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT00585195. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*